×ðÁú¿­Ê±

EN
EN
  • ÓªÒµ×Éѯ

    Öйú£º

    Email: marketing@medicilon.com.cn

    ÓªÒµ×ÉѯרÏߣº400-780-8018

    £¨½öÏÞЧÀÍ×Éѯ £¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©

    ´¨É³×ܲ¿µç»°: +86 (21) 5859-1500

    ÍâÑó£º

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

ÔÚÏßÁôÑÔ¡Á
µã»÷Çл»
News information
ÐÂÎÅ×ÊѶ

ÈÝÄÉÌåÂѰ״¿»¯ºÍ¸´ÐÔ

2016-01-25
|
»á¼ûÁ¿£º

ÈÝÄÉÌ壺ÔÚijЩÉú³¤Ìõ¼þÏ £¬»ùÒò¹¤³Ì¾úÄÜ»ýÀÛijÖÖÌØÊâµÄÉúÎï´ó·Ö×Ó £¬ËüÃÇÖÂÃܵؼ¯¾ÛÔÚϸ°ûÄÚ £¬»ò±»Ä¤°ü¹ü»òÐγÉÎÞĤÂ㶽ṹ £¬ÕâÖÖË®²»ÈÜÐԵĽṹ³ÆÎªÈÝÄÉÌå¡££¨Inclusion Bodies £¬IB£©¡£

ÈÝÄÉÌåµÄ×é³É¼°ÌØÕ÷

Ò»Ñùƽ³£º¬ÓÐ50%ÒÔÉϵÄÖØ×éÂѰ× £¬ÆäÓàΪºËÌÇÌåÔª¼þ¡¢RNA¾ÛºÏø¡¢ÍâĤÂѰ׵È £¬»·×´»òȱ¿ÚµÄÖÊÁ£DNA £¬ÒÔ¼°Ö¬Ìå¡¢Ö¬¶àÌǵÈ £¬¾ÞϸΪ0.5-1um £¬ÄÑÈÜÓëË® £¬Ö»ÈÜÓÚ±äÐÔ¼ÁÈçÄòËØ¡¢ÑÎËáëҵȡ£
ÈÝÄÉÌåÓëÂѰ×ÖÖÀ༰±í´ïϵͳÎÞ¹Ø £¬½öΪÂѰ׹ýÁ¿±í´ïµÄЧ¹û¡£

ÈÝÄÉÌåÐγɵÄÖ÷ÒªÔµ¹ÊÔ­ÓÉ

1¡¢±í´ïÁ¿¹ý¸ß£ºÔµ¹ÊÔ­ÓÉ¿ÉÄÜÊǺϳÉËÙÂÊÌ«¿ì £¬ÒÔÖÁÓÚûÓÐ×ã¹»µÄʱ¼ä¾ÙÐÐÕÛµþ £¬¶þÁò¼ü²»¿ÉÍêȫ׼ȷµÄÅä¶Ô £¬¹ý¶àµÄÂѰ׼äµÄ·ÇÌØÒìÐÔÁ¬Ïµ £¬ÂѰ×ÖÊÎÞ·¨µÖ´ï×ã¹»µÄÏûÈڶȵÈ¡£       

2¡¢ÖØ×éÂѰ׵ݱ»ùËá×é³É£ºÒ»Ñùƽ³£Ëµº¬Áò°±»ùËáÔ½¶àÔ½Ò×ÐγÉÈÝÄÉÌå 

3¡¢ÖØ×éÂѰ×Ëù´¦µÄÇéÐΣº·¢½Íζȸߣ¨37-42¡æ£©»ò°ûÄÚpH¿¿½üÂѰ׵ĵȵçµãʱÈÝÒ×ÐγÉÈÝÄÉÌå¡£
4¡¢ÖØ×éÂѰ×ÊǴ󳦸˾úµÄÒìÔ´ÂѰ× £¬ÓÉÓÚȱ·¦ÕæºËÉúÎïÖз­ÒëºóÐÞÊÎËùÐèøÀà £¬ÖÂʹÖÐÐÄÌå´ó×Ú»ýÀÛ £¬ÈÝÒ×ÐγÉÈÝÄÉÌå³Áµí¡£½ÓÄɹ²±í´ï·Ö×ÓÅóÙ­µÄÒªÁìÒÔÔöÌí¿ÉÈÜÂѰ׵ıÈÀý¡£

ÊèÉ¢´¿»¯Ï¸¾úÈÝÄÉÌåÂѰ×ÖʵĻù±¾°ì·¨

           ÆÆËéϸ°û
           (Disruption of cell)
           ¡ý
             ÊèÉ¢ÈÝÄÉÌå
     (Seperation of inclusion body)
            ¡ý
             ÏûÈÚÈÝÄÉÌå
     (Dissolve inclusion body)
               ¡ý

                   ÂѰ×ÖʲúÆ·µÄ¹¹Ï󻨏´µÈ¡£

             (Recovery of target protein conformation)

ÈÝÄÉÌåÂѰ״¿»¯ºÍ¸´ÐԵĻù±¾°ì·¨

    ÈÝÄÉÌåÂѰ״¿»¯ºÍ¸´ÐԵİ취


ÂѰ×Öʵĸ´ÐÔÊÇÖØ×éÂѰ״¿»¯ÖÐ×îÒªº¦ºÍ×îÖØ´óµÄÎÊÌâ¡£ÂѰ×ÖʵÄÐÔ×Ó²î±ð £¬Ëù´¦µÄÇéÐβî±ð £¬Ê¹Æä¸´ÐÔÌõ¼þ´ó²»Ïàͬ¡£ÈκÎÒ»¸öÂѰ×Öʶ¼ÓÐÒ»¸ö×î¼ÑµÄ¸´ÐÔÌõ¼þ £¬Ö»ÓÐÑ¡Ôñµ½Á˺ÏÊʵĸ´ÐÔ»º³åÒº £¬Ê¹ÂѰ׵ÃÒÔ׼ȷÕÛµþ £¬²Å»ªÊ¹½øÒ»²½µÄ²ãÎöÊèÉ¢µÃÒÔ˳ËìÍê³É¡£ 

×ðÁú¿­Ê±ÈÝÄÉÌåÂѰ׸´ÐÔÌØµã

»îÐÔÂѰ׵ĽÓÄÉÂʸß
׼ȷµÄ¸´ÐԵIJúÆ·Ò×ÓÚÓë¹ýʧµÄÕÛµþÂѰ×ÖÊÊèÉ¢¡£
ÕÛµþ¸´ÐÔºóÓ¦»ñµÃŨ¶È½Ï¸ßµÄÂѰ×ÖʲúÆ·
¸´ÐÔÀú³ÌºÄʱÉÙ

¸´ÐÔ³£ÓÃÒªÁì

1¡¢Ï¡Ê͸´ÐÔ£ºÖ±½Ó¼ÓÈëË®»ò¸´ÐÔ»º³åÒº £¬ÈõµãÊÇÌå»ýÔöÌí½Ï´ó £¬ºóÐø´¦Öóͷ£ÄÑÌâ¡£
Ï¡ÊÍÂѰ×Ũ¶È£ºÅ¨¶È¸ßÔòÈÝÒ×ÐγɾÛÕûÌ壨½ÏµÍµÄ¸´ÐÔÊÕÂÊ£©¡£ÓÐʱÐèµÍÓÚ0.01mg/mL¡£
Âö³åÁ÷¼Ó¸´ÐÔ£º·ÖÅú´Î¼ÓÈëµ½»º³åÒºÖÐ £¬Ê¹ÕÛµþÖÐÐÄÌå¼á³ÖÔڽϵ͵Äˮƽ¡£Àý£ºÔÚ5-10mg/mLÖÕŨ¶ÈÏ £¬Èܾúø¸´ÐÔÊÕÂʿɴï80%ÒÔÉÏ¡£
2¡¢Í¸Îö¸´ÐÔ£ºÀûÒæÊDz»ÔöÌíÌå»ý £¬Í¨¹ýÖð½¥½µµÍÍâ͸ҺŨ¶ÈÀ´¿ØÖƱäÐÔ¼ÁÈ¥³ýËÙÂÊ £¬ËÙÂÊÂý £¬²»Êʺϴó¹æÄ£²Ù×÷ £¬ÎÞ·¨Ó¦Óõ½Éú²ú¹æÄ£¡£
3¡¢³¬Â˸´ÐÔ£ºÑ¡ÔñºÏÊÊÔØÁô·Ö×ÓÁ¿µÄĤ £¬ÔÊÐí±äÐÔ¼Áͨ¹ýĤ¶øÂѰ×ÖÊͨ²»¹ý¡£ÔÚÉú²úÖн϶àµÄʹÓà £¬¹æÄ£½Ï´ó £¬ÈõµãÊDz»ÊʺÏÑùÆ·Á¿½ÏÉÙµÄÇéÐÎ £¬ÇÒÓÐЩÂѰ׿ÉÄÜÔÚ³¬ÂËÀú³ÌÖв»¿ÉÄæµÄ±äÐÔ£¨ÂѰ×Ⱥ¼¯ÓÚĤÉÏ£©¡£
4¡¢É«Æ×¸´ÐÔ£º¸¨ÖúÊÖ¶Î £¬¼æ¾ßÊèÉ¢¡£
4.1Äý½º¹ýÂ˸´ÐÔ£º³ýÁËÂѰ×ÖÊÔÚ½ºÁ£Öд«ÖʺÍÀ©É¢Íâ £¬ÂѰ×ÖÊÓë½éÖÊÖ®¼ä²¢Ã»Óб¬·¢ÆäËû×÷Ó᣸÷¨¿ÉÒÔÆðµ½Ò»¶¨µÄÒÖÖÆÄý¼¯×÷Óà £¬²¢ÇÒÔÚÄý½º¹ýÂËÖÐëåµÈ±äÐÔ¼ÁÍѳýµÃÏà¶Ô½ÏÂý £¬¶ÔÓÐЩÂѰ×Öʵĸ´ÐÔÓÐÀû¡£
4.2Îü¸½ÐͲãÎö¸´ÐÔ£ºÀë×Ó½»Á÷¡¢ÊèË®²ãÎö¡¢Ç׺ͲãÎöºÍÀ©ÕÅ´²²ãÎö¾ùÊôÓÚÎü¸½²ãÎö¡£Æä»ù±¾¸´ÐÔÔ­ÀíÊDzãÎöÖùƽºâºó £¬½«±äÐÔÂѰ×ÉÏÑù²¢Îü¸½ÔÚÄý½º½éÖÊÉÏ £¬È»ºóÓÃϴ媻º³åҺϴµôδÎü¸½µÄ±äÐÔ¼ÁºÍÔÓÂѰ× £¬×îºóÓø´ÐÔ»º³åÒº½«Îü¸½µÄÂѰ×Ï´ÍÑÏÂÀ´ £¬ÔÚÏ´ÍÑÀú³ÌÖÐÍê³É¸´ÐÔ¡£
5¡¢·Ö×ÓÅóÙ­£ºÖ÷Òª°üÀ¨ÁòÑõ»¹ÂѰ׶þÁò¼üÒ칹ø¡¢ëÄõ£Ò»¸¨°±õ£Ë³·´Ò칹øµÈ¡£·Ö×ÓÅóÙ­ºÍÕÛµþøµÈ²»µ«¿ÉÔÚϸ°ûÄÚµ÷ÀíÂѰ×ÖʵÄÕÛµþºÍȺ¼¯Àú³ÌµÄƽºâ £¬²¢ÇÒ¿ÉÔÚÌåÍâÔö½øÂѰ×ÖʵÄÕÛµþ¸´ÐÔ¡£

    ÌåÄÚ¸´ÐÔÖ÷ÒªÊÇÔÚ¹¤³Ì¾ú×÷ÓýÀú³ÌÖÐͬʱ¼ÓÈë·Ö×ÓÅóÙ­µÄ»ùÒò¾ÙÐй²±í´ï£»ÌåÍ⸴ÐÔÖ÷ÒªÊǽ«»ùÒò¹¤³Ì¾úÖÐÈÝÄÉÌåÏûÈÚ £¬ÔÙ¼ÓÈë·Ö×ÓÅóÙ­×ÊÖúÕÛµþ¡£

ÁªÏµ×ðÁú¿­Ê±

    ÓÊÏ䣺marketing@medicilon.com.cn

    µç»°£º02158591500



Ïà¹ØÐÂÎÅ
ÂѰ״¿»¯Ð§À͹«Ë¾
2016-05-13
ÂѰױí´ï´¿»¯Ð§ÀͰüÀ¨ÃÜÂë×ÓÓÅ»¯¡¢»ùÒòºÏ³É¡¢±í´ïÔØÌåµÄ¹¹½¨¡¢Ð¡¹æÄ£µÄÂѰױí´ïÓë´¿»¯ºÍ´ó¹æÄ£µÄÂѰױí´ïÓë´¿»¯µÈ¡£
ÂѰ״¿»¯ÒªÁì´óÈ«¼°ÓÅÈõµã½ÏÁ¿
2016-01-11
ÂѰ×ÖʵÄÊèÉ¢´¿»¯ÊÂÇé½ÏÎªÖØ´ó £¬´Óϸ°ûÖÐÌáÈ¡µÄÂѰ×ÖÊ»ò´Óº¬ÓÐÂѰ×ÖʵÄÈÜÒºÖо­ÓɳÁµí¡¢ÌݶÈÀëÐÄ¡¢ÑÎÎöµÈÒªÁì»ñµÃµÄÂѰ×Öʾ­³£º¬ÓÐÔÓÖÊ £¬ÒªÈ¥³ýÕâЩÔÓÖÊ £¬Í¬Ê±ÓÖÒª¼á³ÖÂѰ×ÖʵÄÉúÎïѧ»îÐÔ £¬ÈçøµÄ´ß»¯»îÐÔ £¬¾ÍÐèҪƾ֤²î±ðµÄÂѰ×ÖÊÖÆ¶©³öÏìÓ¦µÄÕ½ÂÔ £¬½ÓÄɲî±ðµÄÒªÁì¡£
ͨ¹ýÔöÇ¿MTUS1ÎȹÌÐÔÒÖÖÆÍ¸Ã÷ϸ°ûÉöϸ°û°©×ªÒÆ £¬±¾Ñо¿ÖÐÌåÍâʵÑéÖØ×éÂѰ×ͨ¹ý×ðÁú¿­Ê±ºÏ³ÉºÍ´¿»¯
2025-06-12
Clear cell renal cell carcinoma (ccRCC) is the most prevalent histological subtype of kidney cancer and is believed to mainly originate from proximal tubular epithelial cells of the nephron. MTUS1 was significantly downregulated in ccRCC tissues, especially in metastatic tissues. Knockdown of MTUS1 decreased microtubule stability, whereas increased microtubule dynamics by promoting the ratio of unphosphorylated KIF2CS192 adapting to high motility of metastatic cancer cells. MTUS1 is a potent microtubule-stabilizing protein19, so we assessed the impact of MTUS1 knockdown on microtubule dynamics. MTUS1 regulates microtubule dynamics via promoting KIF2CS192 phosphorylation by Aurora B. Western blot and immunohistochemistry further confirmed significantly lower expression of SORBS2 protein in metastatic tissues than that in primary tissues and normal tissues.
¡Á
ËÑË÷ÑéÖ¤
µã»÷Çл»
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿